

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Use of an  $\alpha_v$ - integrin antagonist for the manufacture of a medicament for the treatment of pathological conditions in a mammal in which activated fibroblast or myofibroblasts are involved.
2. (Original) Use according to claim 1, wherein the  $\alpha_v$ -integrin antagonist is an  $\alpha_v\beta_3$  antagonist.
3. (Original) Use according to claim 1, wherein the  $\alpha_v$ -integrin antagonist is an  $\alpha_v\beta_6$  antagonist.
4. (Currently Amended) Use of claim 2 or 3, wherein the the  $\alpha_v$ -integrin antagonist is selected from the group consisting of
  - (i) 3-Benzo[1,2,5]thiadiazol-5-yl-3-{6-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-1H-indol-3-yl}-propionic acid, and
  - (ii) 3-{3-Benzoyloxy-2-[5-(pyridin-2-ylamino)-pentanoylamino]-propanoylamino}-3-(3,5-dichloro-phenyl)-propionic acid.
5. (Currently Amended) Use according to claim 1 ~~any of the claims 1—4~~, wherein the pathological condition is fibrosis or a fibrotic disease.
6. (Original) Use according to claim 5, wherein the fibrosis is a fibrotic liver disease.
7. (Original) Use according to claim 6, wherein said fibrotic liver disease is liver cirrhosis.
8. (Original) Use according to claim 5, wherein said antagonist inhibits PDGF-induced HSC/MF migration and / or activation.

9. (Original) Use according to claim 5, wherein said antagonist inhibits scarring.